XyloCor Therapeutics is a biopharmaceutical company intended to develop gene therapy for people with coronary artery disease.
XyloCor Therapeutics has raised $67.5M in total funding. The most recent round was Series B. The last funding was announced in January 2025.
XyloCor Therapeutics's investors include Jeito Capital, EQT Life Sciences, Longwood Fund, Lumira Ventures, Sofinnova Investments.
XyloCor Therapeutics is headquartered in King Of Prussia, United States.
XyloCor Therapeutics is a biopharmaceutical company intended to develop gene therapy for people with coronary artery disease.
XyloCor Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"XyloCor Therapeutics — Funding & Investors." VCBacked, January 7, 2025, https://www.vcbacked.co/company/xylocor-therapeutics. Accessed August 1, 2026.
VCBacked. (2025). XyloCor Therapeutics — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/xylocor-therapeutics
{{cite web |title=XyloCor Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/xylocor-therapeutics |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated